Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Ascending Dose Study of Intravenous ATYR1923 in Pulmonary Sarcoidosis
2018-004244-33Phase 2Completed
- Sponsor
- aTyr Pharma
- Start
- Jul 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary sarcoidosis comparing ATYR1923 arm with Placebo arm (2 arms). Primary endpoint: Primary: Safety and tolerability of multiple IV doses of ATYR1923. Started Jul 2019; status: completed.
02
Drugs
efzofitimod
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on 2018-004244-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004244-33.